About the meeting
The pediatric patient population with chemotherapy-induced hearing loss represents a segment of the cancer survivor community with a severe burden of disease with great unmet medical need. An externally-led, FDA-approved Patient Focused Drug Development (PFDD) meeting was held on September 13, 2018 near Washington, DC to explore these issues in-depth.
Location: College Park Marriott Hotel & Conference Center in Hyattsville, MD
The half-day meeting (1pm-5pm) followed the FDA model for externally-led PFDD meetings and featured a series of facilitated panel and audience discussions, and a webinar with live polling focused on providing the FDA and other stakeholders with patient views on key issues such as:
Burden of the condition (physical, emotional, financial issues) impacting daily health-related quality of life;
Assessments of current and potential future treatments;
Benefits that patients with chemotherapy-induced hearing loss are looking for in treatments and the risks they are willing to assume in return for more advanced interventions;
Participation in clinical trials and ideas on trial design to make them more appealing to people with chemotherapy-induced hearing loss.